user-generated· earnings
Novo Nordisk reports Wegovy pill revenue above £100m by Q1 2027
Novo Nordisk's oral Wegovy, priced competitively with the injectable version, will drive strong revenue growth as UK market penetration accelerates. Clinical preference for the pill format will further boost early sales.
earnings · Prediction Market
- Implied probability (Yes)
- 70%
- Closes
- 2027-03-31
More earnings markets
- Forum AI raises $50M+ in Series B funding by 2027-03-31 — 60% Yes
- Anthropic's compute deal with xAI will underperform revenue targets by Q4 2026 — 70% Yes
- Titleist sells more clubs than Callaway in 2026 — 72% Yes
- Sadi Thermal Machines secures $50M+ funding round by 2027 — 70% Yes
- Lime achieves profitability within 12 months post-IPO — 55% Yes
- SK Hynix ADRs to price at or above midpoint range by July 10 — 75% Yes
- Flexjet stock rises 15% by Q4-2027 on fuel cost advantage — 70% Yes
- Driving instructor revenue drops 15% in Q3 2027 due to test booking changes — 68% Yes
Loading…